<scp>CDK4</scp>/6 Inhibitor Can Improve Niraparib Sensitivity and Reverse Acquired Drug Resistance Through Endonuclease G Nuclear Translocation in <scp>BRCA</scp> Wild‐Type Ovarian Cancer: A Vitro Study
Combined therapy with the CDK4/6 inhibitor TQB-3616 and niraparib ZL-2306 showed synergistic antitumour effects against BRCA wild-type ovarian cancer without increasing the toxicity of each drug. The antitumour effect may be related to mitochondrial apoptosis, where EndoG nuclear translocation plays a critical role. This study proposes combined therapy of CDK4/6 and PARP inhibitors as a novel approach for the treatment of refractory ovarian cancer.
Authors
- Xiaoxia Che (ORCID: https://orcid.org/0000-0002-1003-1092)
- Fangfang Jian (ORCID: https://orcid.org/0000-0002-4032-3264)
- Xiang Wang (ORCID: https://orcid.org/0000-0002-1522-9532)
- Weiwei Feng (ORCID: https://orcid.org/0000-0002-2923-1713)
- Yahui Jiang (ORCID: https://orcid.org/0000-0001-8233-8299)
- Tianyu Zhou (ORCID: https://orcid.org/0000-0002-9495-5451)
Institutions
- Ruijin Hospital (CN)
Publication Details
- Journal
- BJOG An International Journal of Obstetrics & Gynaecology
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1111/1471-0528.18177
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China